论文部分内容阅读
目的：评价自体骨髓移植（ＡＢＭＴ）治疗急性白血病的疗效。方法：自１９８６年１０月至１９９７年１２月，用ＡＢＭＴ治疗急性白血病７３例，中位年龄２５．５（９～４８）岁。其中急性非淋巴细胞白血病（ＡＮＬＬ）４３例（ＣＲ１３５例，ＣＲ２或早期复发８例），急性淋巴细胞白血病（ＡＬＬ）３０例（ＣＲ１２５例，ＣＲ２或早期复发５例）。预处理方案包括环磷酰胺（ＣＴＸ）１２０ｍｇ／ｋｇ＋单次全身照射（ＳＴＢＩ）９～１０Ｇｙ或马利兰（Ｂｕ）１６ｍｇ／ｋｇ或马法兰（Ｍｅｌ）１６０～１８０ｍｇ／ｍ２＋阿糖胞苷（ＡｒａＣ）４ｇ／ｍ２。结果：所有患者移植后均重建造血，中位随访时间８０６（３２～３４００）天，移植相关死亡７例（９．５％），ＡＮＬＬ、ＡＬＬＣＲ１期移植者３年无病生存率分别为５４９％±７．７％和６７．０％±１０６％，复发率３９．３％±９．３％和２３．７％±１０．６％。结论：为降低白血病复发率和提高患者无病生存率，无骨髓供者的ＣＲ１期急性白血病患者适合接受ＡＢＭＴ。
Objective: To evaluate the efficacy of autologous bone marrow transplantation (ABMT) in the treatment of acute leukemia. METHODS: From October 1986 to December 1997, 73 patients with acute leukemia were treated with ABMT, with a median age of 25.5 (9 to 48) years. Of these, 43 were acute non-lymphocytic leukemia (ANLL) (135 cases of CR, 8 cases of CR2 or early recurrence), and 30 cases of acute lymphoblastic leukemia (ALL) (CR125 cases, CR2 or early recurrence of 5 cases). Pretreatment regimens include cyclophosphamide (CTX) 120 mg/kg + single-shot whole body (STBI) 9-10 Gy or mulilan (Bu) 16 mg/kg or Mel 160-180 mg/m2 Ara-C 4g/m2. Results: All patients were reconstituted with blood after transplantation. The median follow-up time was 806 (32-3 400) days, and 7 deaths (9.5%) were associated with transplant death. The 3-year disease-free survival rate of ANLL and ALLCR stage 1 transplants was 54. 9%±7.7% and 67.0%±10.6%, the recurrence rate was 39.3%±9.3% and 23.7%±10.6%. CONCLUSIONS: In order to reduce the recurrence rate of leukemia and improve the disease-free survival of patients, CR1-stage acute leukemia patients without bone marrow donors are eligible for ABMT.